Additionally, he helped lead Agios’ transition from an early-stage research company to a late-stage clinical organization with lead assets enasidenib and ivosidenib (now marketed as IDHIFA ® and ...

he helped lead Agios’ transition from an early-stage research company to a late-stage clinical organization with lead assets enasidenib and ivosidenib (now marketed as IDHIFA ® and TIBSOVO ...

Glioblastoma, a grade IV astrocytoma, typically has a poor prognosis, with most patients succumbing within eighteen months of diagnosis and few experiencing long-term survival. Focused ultrasound, an ...

In the same batch of announcements Ivosidenib (Tibsovo) was also accepted for treating adults with advanced cholangiocarcinoma, a cancer of the bile ducts. Teclistamab (Tecvayli) was accepted as well, ...